321 related articles for article (PubMed ID: 18313840)
1. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
Hosny G; Farahat N; Tayel H; Hainaut P
Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
Hosny G; Farahat N; Hainaut P
Cancer Lett; 2009 Mar; 275(2):234-9. PubMed ID: 19046801
[TBL] [Abstract][Full Text] [Related]
3. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
[TBL] [Abstract][Full Text] [Related]
4. [Universal presence of HBVx gene and its close association with hotspot mutation of p53 gene in hepatocellular carcinoma of prevalent area in China].
Zhang F; Zhu Y; Sun Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):18-21. PubMed ID: 10921048
[TBL] [Abstract][Full Text] [Related]
5. TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.
Szymañska K; Chen JG; Cui Y; Gong YY; Turner PC; Villar S; Wild CP; Parkin DM; Hainaut P
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1638-43. PubMed ID: 19366907
[TBL] [Abstract][Full Text] [Related]
6. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry.
Lleonart ME; Kirk GD; Villar S; Lesi OA; Dasgupta A; Goedert JJ; Mendy M; Hollstein MC; Montesano R; Groopman JD; Hainaut P; Friesen MD
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2956-62. PubMed ID: 16365016
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.
Stern MC; Umbach DM; Yu MC; London SJ; Zhang ZQ; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):617-25. PubMed ID: 11401911
[TBL] [Abstract][Full Text] [Related]
8. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
[TBL] [Abstract][Full Text] [Related]
9. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
11. P53 mutations in hepatocellular carcinoma patients in Egypt.
El-Kafrawy SA; Abdel-Hamid M; El-Daly M; Nada O; Ismail A; Ezzat S; Abdel-Latif S; Abdel-Hamid A; Shields PG; Loffredo C
Int J Hyg Environ Health; 2005; 208(4):263-70. PubMed ID: 16078640
[TBL] [Abstract][Full Text] [Related]
12. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation.
Volkmann M; Hofmann WJ; Müller M; Räth U; Otto G; Zentgraf H; Galle PR
Oncogene; 1994 Jan; 9(1):195-204. PubMed ID: 8302580
[TBL] [Abstract][Full Text] [Related]
13. Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients.
Jackson PE; Kuang SY; Wang JB; Strickland PT; Muñoz A; Kensler TW; Qian GS; Groopman JD
Carcinogenesis; 2003 Oct; 24(10):1657-63. PubMed ID: 12869416
[TBL] [Abstract][Full Text] [Related]
14. A p53 polymorphism modifies the risk of hepatocellular carcinoma among non-carriers but not carriers of chronic hepatitis B virus infection.
Zhu ZZ; Cong WM; Liu SF; Xian ZH; Wu WQ; Wu MC; Gao B; Hou LF; Zhu GS
Cancer Lett; 2005 Nov; 229(1):77-83. PubMed ID: 15979781
[TBL] [Abstract][Full Text] [Related]
15. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
[TBL] [Abstract][Full Text] [Related]
16. P53 codon 249 mutation in hepatocellular carcinomas from Nigeria.
Ndububa DA; Yakicier CM; Ojo OS; Adeodu OO; Rotimi O; Ogunbiyi O; Ozturk M
Afr J Med Med Sci; 2001; 30(1-2):125-7. PubMed ID: 14510167
[TBL] [Abstract][Full Text] [Related]
17. p53 gene in hepatocellular carcinomas from Australia.
Vesey DA; Hayward NK; Cooksley WG
Cancer Detect Prev; 1994; 18(2):123-30. PubMed ID: 8025894
[TBL] [Abstract][Full Text] [Related]
18. Ser-249TP53 mutation in tumour and plasma DNA of hepatocellular carcinoma patients from a high incidence area in the Gambia, West Africa.
Szymańska K; Lesi OA; Kirk GD; Sam O; Taniere P; Scoazec JY; Mendy M; Friesen MD; Whittle H; Montesano R; Hainaut P
Int J Cancer; 2004 Jun; 110(3):374-9. PubMed ID: 15095302
[TBL] [Abstract][Full Text] [Related]
19. Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention.
Anwar WA; Khaled HM; Amra HA; El-Nezami H; Loffredo CA
Mutat Res; 2008; 659(1-2):176-84. PubMed ID: 18346933
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus mutations associated with in situ expression of hepatitis B core antigen, viral load and prognosis in chronic hepatitis B patients.
Zhu R; Zhang HP; Yu H; Li H; Ling YQ; Hu XQ; Zhu HG
Pathol Res Pract; 2008; 204(10):731-42. PubMed ID: 18597951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
